In metastatic prostate cancer, miR-135a inhibited tumor progression by decreasing epidermal growth factor receptor (EGFR)29, and its silencing resulted in increased AR axis activity, thus contributing to disease progression65. The gene discussed is EGFR; the disease is neoplasm.